Publications by authors named "Haruhito Azuma"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

17,964

Total Likes

186

Extended Reach

17,964

Social Features

102
C
Current treatment strategies for advanced prostate cancer.
Kazumasa Komura, Christopher J Sweeney, Teruo Inamoto, Naokazu Ibuki, Haruhito Azuma, Philip W Kantoff

March 2018

Videos about Article: user user

2 100 8

View All Article and Social Media Activity
P
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab.
Keiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, Satoshi Katayama, Ryoichi Maenosono, Haruhito Azuma

Int J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.
Tomoki Shirafuji, Yasutaka Yamada, Kodai Sato, Zhao Xue, Takuya Tsujino, Haruhito Azuma

BJU Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.
Kyosuke Nishio, Kensuke Hirosuna, Taizo Uchimoto, Heima Niigawa, Sho Kakumae, Haruhito Azuma, Kazumasa Komura

Anticancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium.
Taizo Uchimoto, Kensuke Hirosuna, Heima Niigawa, Sho Kakumae, Hirofumi Morinaka, Haruhito Azuma, Kazumasa Komura

Jpn J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote monitoring-assisted APD in a remote island setting.
Hajime Hirano, Takahiro Inoue, Yu Munakata, Hideaki Fujisaki, Haruhito Azuma

Perit Dial Int· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study.
Yosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, Zhao Xue, Kodai Sato, Haruhito Azuma

Jpn J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy.
Koichi Sugimoto, Takafumi Minami, Shingo Toyoda, Lan Inoki, Takuhisa Nukaya, Haruhito Azuma

Anticancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vesical perfusion volume and internal iliac pressure during double balloon-occluded arterial infusion chemotherapy for bladder cancer.
Kiyohito Yamamoto, Kazuhiro Yamamoto, Hiroshi Juri, Haruhito Azuma, Keigo Osuga

Eur Radiol Exp· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, Takafumi Minami, Wataru Fukuokaya, Haruhito Azuma

Transl Androl Urol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy.
Tatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Kazumasa Komura, Kazuma Tsuboi, Haruhito Azuma

Sci Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.
Taizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Haruhito Azuma

Int J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Yasutaka Yamada, Kodai Sato, Shinichi Sakamoto, Takuya Tsujino, Sinpei Saito, Kazumasa Komura, Haruhito Azuma

Int J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.
Yasutaka Yamada, Shinichi Sakamoto, Takuya Tsujino, Sinpei Saito, Kodai Sato, Kazumasa Komura, Haruhito Azuma

Prostate Int· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact.
Tatsuo Fukushima, Takuya Tsujino, Moritoshi Sakamoto, Kiyoshi Takahara, Kazumasa Komura, Haruhito Azuma

World J Urol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Taizo Uchimoto, Kengo Iwatsuki, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Haruhito Azuma

Int J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A CASE OF SEVERE DRUG INDUCED ERUPTION AFTER APALUTAMIDE USE FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, WHICH WAS DETERIORATED FROM TEMPORARY REMISSION AFTER DRUG WITHDRAWAL].
Baku Iijima, Teruo Inamoto, Hirofumi Uehara, Kazumasa Komura, Haruhito Azuma

Nihon Hinyokika Gakkai Zasshi· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy.
Shingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Kazumasa Komura, Haruhito Azuma

Jpn J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor.
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, Takafumi Minami, Wataru Fukuokaya, Haruhito Azuma

Int J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, Satoshi Katayama, Taizo Uchimoto, Kazumasa Komura, Haruhito Azuma

Urol Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: a multicenter, prospective study.
Nobuyuki Hinata, Sae Murakami, Yuzo Nakano, Isao Hara, Tsunenori Kondo, Haruhito Azuma

Int J Clin Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma.
Kazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, Mitsuaki Ishida, Kensuke Hirosuna, Haruhito Azuma

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
Taketo Kawai, Hideyasu Matsuyama, Keita Kobayashi, Atsushi Ikeda, Makito Miyake, Haruhito Azuma

Int J Urol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Taizo Uchimoto, Takuya Matsuda, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Haruhito Azuma

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Taizo Uchimoto, Shuya Tsuchida, Kazumasa Komura, Wataru Fukuokaya, Takahiro Adachi, Haruhito Azuma

Target Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of Management of Lifestyle-Related Diseases After Kidney Donation to Living Donors.
Hajime Hirano, Yuya Fujiwara, Tomota Okabe, Keita Nakamori, Koichiro Minami, Kazumasa Komura, Haruhito Azuma

Transplant Proc· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis